Klinikum Mutterhaus der Borromaeerinnen gGmbH — Clinical Trial Site

43 Registered trials

21 Currently recruiting

Organisation

Klinikum Mutterhaus der Borromaeerinnen gGmbH

Location

Trier, Germany

Identifier

ORG-100023890

Address

Feldstrasse 16, Innenstadt, 54290, Germany

Departments

Abt. für Innere Medizin
Abteilung für Innere Medizin I (Onkologie)
Apotheke
Darmkrebszentrum
Gynaekologie
Gynaekologie und Geburtshilfe
Gynäkolgie
Gynäkologie
Gynäkologischen Krebszentrums
Gynecology and Obstetrics
Hämatologie/Onkologie
Hemato-Oncology
Hematology
Hematology/Oncology
I. Medizinische Klinik
Innere Medizin
Innere Medizin 1
Innere Medizin I
Innere Medizin I Hämato-Onkologie, Infektiologie, Gastroenterologie
Inneren Medizin 1; Hämatologie und Onkologie
Internal Medicine
Internistische Onkologie
Klinik für Gynäkologie
Klinikum Mutterhaus der Borromäerinnen - Innere Medizin 1
Klinikum Mutterhaus der Borromäerinnen gGmbH
Krankenanstalt, Med. Abteilung I
Medizinische Klinik
MVZ Strahlentherapie
N/A
NA
Onkologisches Zentrum

Clinical trials at this site (43)

Search interface

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
This study is to find out about the Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in… Ended

2023-505628-67-00 Relapsed and Refractory Follicular Lymphoma 5 2022-10-28
A phase II, open-label, single arm study to evaluate the efficacy of Luspatercept in Erythropoiesis-stimulating agent naive lower-risk MDS p… Ended

2024-516438-36-00 Patients with very low, low or intermediate risk myelod 4 2022-09-13
A clinical trial to compare the effectiveness and safety of giredestrant with a subcutaneous combination of pertuzumab and trastuzumab versu… Ended

2022-500014-26-00 Locally-Advanced unresectable or Metastatic breast canc 5 2022-06-24
Phase Ib/III Study of Capivasertib + CDK4/6 Inhibitors + Fulvestrant as Treatment for Advanced/Metastatic HR+/HER2-Breast Cancer (CAPItello-… Ended

2023-504997-39-00 Hormone Receptor-Positive and Human Epidermal Growth Fa 5 2021-06-14
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Pa… Ended

2023-506911-16-00 ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVAN 5 2020-12-04
FOLFOX before surgey compared to risk-adapted chemotherapy after surgery in patients with locally advanced rectal cancer and low risk for lo… Ended

2024-518077-34-00 locally advanced rectal cancer 5 2020-09-30
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant versus Placebo Plus Palbociclib and Fulvestrant in… Ended

2023-505812-39-00 HR+/HER2-Negative Locally Advanced or Metastatic Breast 5 2020-08-28
A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi… Ended

2023-509242-35-00 HR+/HER2- early breast cancer 5 2020-07-23
Short course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined… Ended

2024-511577-29-01 intermediate and high-risk rectal cancer 5 2020-03-13
HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended

2022-502478-18-00 Acute Myeloid Leukemia (AML) 4 2019-12-20
Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagno… Ended

2023-503670-21-00 Patients with newly diagnosed AML and intermediate- or 5 2019-08-28
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk… Ended

2024-515769-32-00 HR+/HER2- early breast cancer 5 2019-07-02
Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio… Ended

2022-502832-37-00 Acute myeloid leukemia 5 2019-03-01
A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) inductio… Ended

2024-513464-26-00 Multiple Myeloma 5 2018-10-18
DANTE / FLOT8 A randomized, open-label Phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in … Ended

2024-514945-12-00 locally advanced resectable adenocarcinoma of the oesop 10 2018-09-03
CIRCULATE Ended

2023-506715-18-00 colon cancer stage II, rectal cancer stage II 5 2019-12-04
autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea… Ended

2024-511235-10-00 Generalized mantle cell Lymphoma 5 2016-07-25
HD21 Ended

2024-518022-33-00 Advanced Stage of Hodgkin Lymphoma 5 2016-07-15